[{"orgOrder":0,"company":"University Hospitals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cetylpyridinium Chloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospitals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"University Hospitals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University Hospitals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Cetylpyridinium Chloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University Hospitals

                          Country arrow
                          Antibody Engineering
                          Not Confirmed

                          University Hospitals

                          Country arrow
                          Antibody Engineering
                          Not Confirmed

                          Details : The trial, named the ARMS-I COVID Study, is designed to assess whether ARMS-I helps prevent airborne transmission of coronavirus and whether it reduces the symptoms of healthcare providers who have tested positive for the virus.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 06, 2020

                          Lead Product(s) : Cetylpyridinium Chloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank